2076975 2077203
최종편집 2024-03-03 17:58 (일)
Sanofi’s Xenpozyme receives approval from Korea
상태바
Sanofi’s Xenpozyme receives approval from Korea
  • Hyeokgi Lee, Newsmp
  • 승인 2023.07.26 17:17
  • 댓글 0
이 기사를 공유합니다

[Newsmp] Korea’s Ministry of Food and Drug Safety said on Wednesday it has approved Sanofi-Aventis Korea’s acid sphingomyelinase deficiency (ASMD) therapy Xenpozyme (ingredient: olipudase alfa).

ASMD arises from a deficiency in an essential enzyme responsible for breaking down a complex lipid known as sphingomyelin, leading to its accumulation in the liver, spleen, lungs, and brain.

Xenpozyme is a recombinant human ASM that reduces sphingomyelin (SM) accumulation in the patient’s organs.

"We will continue to do our best to promptly supply treatments with sufficient safety and effectiveness based on regulatory science," the ministry said in a release.


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.